While decreased IL-33 signaling has been associated with preeclampsia, the mechanisms linking this signaling pathway to disease pathophysiology are not well understood. In this episode, Associate Editor Dr. Amanda LeBlanc (University of Louisville) interviews author Dr. Denise Cornelius (University of Mississippi Medical Center) and expert Dr. Stella Goulopoulou (Loma Linda University) about the new research study by Wang et al. Using the Reduced Uterine Perfusion Pressure (RUPP) rat model, the authors found evidence that mechanistically links reduced IL-33 with the inflammatory response and vascular dysfunction present in preeclampsia. Is the IL-33 signaling pathway a possible clinical therapeutic target for the treatment of preeclampsia? Listen now to learn more.   Xi Wang, Corbin Shields, Geilda Tardo, Greg Peacock, Emily Hester, Marissa Anderson, Jan M. Williams, Denise C. Cornelius IL-33 supplementation improves uterine artery resistance and maternal hypertension in response to placental ischemia Am J Physiol Heart Circ Physiol, published April 3, 2024. DOI: 10.1152/ajpheart.00045.2024